At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
6 の 4 を表示する
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma 4.0 portfolio, the Conductor 4.0 control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
To support community engagement, GEA offers employees one day of paid time off per year.
How do you lead a dairy farm into the next generation while ensuring a sustainable future and animal welfare while managing increasing complexity? This is a question almost every dairy farmer around the world must consider. The...
After reaching its Mission 26 targets two years early, GEA launches Mission 2030 strategy with focus on growth, value and making a positive impact.